Morningstar

Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...
Seeking Alpha

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trialRESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE ...
Morningstar

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC ...

Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ ...
Nature

Data Monitoring Committees in Clinical Trials

Data Monitoring Committees (DMCs) play a pivotal role in safeguarding participant safety and ensuring the integrity of clinical trials. Operating independently from trial sponsors and investigators, ...
Monthly Prescribing Reference

Oral Tebipenem HBr Noninferior to IV Imipenem-Cilastatin for Complicated UTI

Based on these findings, the Independent Data Monitoring Committee recommended the trial stop early. Topline data were announced from a phase 3 trial evaluating tebipenem pivoxil hydrobromide (HBr) in ...
Business Wire

Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation (Humanetics) is pleased to announce the positive results from the independent Data Safety Monitoring Board (DSMB) review of its phase 2 clinical ...
PharmiWeb

Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...